Insmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent

Insmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent


Insmed Incorporated , a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United States Patent and Trademark Office issued U.S. Patent Number 9,566,234 for ARIKAYCE, the Company's liposomal amikacin for inhalation. The claims of the patent relate in part to systems and methods for treating pulmonary infections, including nontuberculous mycobacteria infections.



from Biotech News